List view / Grid view
Stem cells are undifferentiated biological cells that can differentiate into specialised cells and can divide to produce more stem cells.
Scaling up cell therapy is no easy feat. PluriCDMO's Andy Lewin reveals the critical factors for success and how they are helping companies bring life-saving therapies to market.
19 February 2025 | By
Discover the transformative potential of iPSC-based therapies in regenerative medicine, alongside their challenges including scalability, safety and targeted delivery.
Download our latest report to discover how stem cell research is revolutionising treatments for chronic diseases, cancer and regenerative medicine.
17 January 2025 | By Drug Target Review
Join this webinar to learn how organoids are reshaping drug discovery by providing more accurate models for disease research and drug testing, offering new solutions to long-standing challenges in the industry.
Deep Science Ventures and General Inception are teaming up to tackle fibrosis. Together, they aim to create a company focused on developing new treatments for fibrotic diseases.
The human body has an incredible ability to repair itself, both from acute trauma and chronic damage that accumulates as we age. Here, Cameron Lee, Principal Scientist at Tune Therapeutics, reveals the potential of harnessing the body’s natural regenerative capabilities with epigenetic control of stem cells.
New insights into the role of SUMOylation in the brain could lead to new targeted therapies for neurodegenerative conditions.
Developing cell therapies solely with healthy donor material can jeopardise clinical outcomes, introducing risks ranging from faulty preclinical data to manufacturing failures. We spoke to Priya Baraniak, CBO at OrganaBio, who advocates for early integration of diseased donor material, improved biobanking infrastructure, and cross-industry collaboration to develop more effective, patient-relevant…
Findings show that alpha-synuclein and an immune response are required for Lewy body formation, in an effect specific to dopaminergic neurons.
By studying organoids derived from adult stem cells, researchers made a discovery that could improve the development of personalised therapeutics.
Cincinnati Children’s have repaired damaged intestines in a rodent model, moving research efforts closer to clinical trials.
Understanding the signalling pathway controlling neural stem cell reactivation could offer a strategy for using existing drugs to treat neurodevelopmental disorders.
31 July 2024 | By bit.bio
Watch this webinar to discover the latest astrocyte research and its implications for CNS drug discovery.
The agreement between Cartherics, The University of Sydney and The University of Queensland will further stem cell-derived heart muscle therapy for heart failure.
Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma.
